Compare DHC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | PHVS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Switzerland |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 2020 |
| Metric | DHC | PHVS |
|---|---|---|
| Price | $8.76 | $34.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $8.00 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.8M | 544.3K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $19.12 |
| 52 Week High | $9.66 | $36.60 |
| Indicator | DHC | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 62.03 |
| Support Level | $8.19 | $24.73 |
| Resistance Level | $9.14 | N/A |
| Average True Range (ATR) | 0.33 | 1.65 |
| MACD | -0.07 | 0.10 |
| Stochastic Oscillator | 12.13 | 67.66 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.